INVESTIGACIÓN E INNOVACIÓN EN LA ENFERMEDAD CARDIOVASCULAR
Hospital General Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (8)
2023
-
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis
Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75
2022
-
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry
European Journal of Clinical Investigation, Vol. 52, Núm. 12
-
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529
2021
-
Sex-Specific Ventricular Arrhythmias and Mortality in Cardiac Resynchronization Therapy Recipients
JACC: Clinical Electrophysiology, Vol. 7, Núm. 6, pp. 705-715
2010
-
Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma
Genes Chromosomes and Cancer, Vol. 49, Núm. 5, pp. 439-451
2008
-
Comparison of Benefits and Mortality in Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation Versus Patients in Sinus Rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] Study)
American Journal of Cardiology, Vol. 102, Núm. 4, pp. 444-449
2005
-
Resincronización en la insuficiencia cardíaca. ¿Con o sin desfibrilador?
Revista Espanola de Cardiologia Suplementos, Vol. 5, Núm. B
1997
-
Role of Doppler echocardiography in the management of chronic coronary artery disease
Revista Espanola de Cardiologia, Vol. 50, Núm. 1, pp. 15-25